Giorgio Fassina

Giorgio Fassina

Auto-generated profile, based on publicly available information

Giorgio Fassina

Xeptagen S.p.A., Venice, Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1986 in Biochemistry
Verified
Journal Article
Closed access
AFAngelo Fontana
Angelo Fontana
GFGiorgio Fassina
Giorgio Fassina
CVClaudio Vita
Claudio Vita
DDDaniele Dalzoppo
Daniele Dalzoppo
MZMoreno Zamai
Moreno Zamai
MZMarcello Zambonin
Marcello Zambonin

1 October 2001 in Journal of Biochemical and Biophysical Methods
Verified
Journal Article
Closed access
GFGiorgio Fassina
Giorgio Fassina
MRMenotti Ruvo
Menotti Ruvo
GPGiovanna Palombo
Giovanna Palombo
AVAntonio Verdoliva
Antonio Verdoliva
MMMaria Marino
Maria Marino

1 October 1996 in Journal of Molecular Recognition
Verified
Journal Article
Closed access
PDF file
GFGiorgio Fassina
Giorgio Fassina
AVAntonio Verdoliva
Antonio Verdoliva
MOMaria Rosaria Odierna
Maria Rosaria Odierna
MRMenotti Ruvo
Menotti Ruvo
GCGiovanni Cassini
Giovanni Cassini

17 February 2004 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Patrizia PontissoPatrizia Pontisso
Patrizia Pontisso
FCF Calabrese
F Calabrese
LBL Benvegnù
L Benvegnù
MLM Lise
M Lise
CBC Belluco
C Belluco
GFG Fassina
G Fassina
Pathogenetic mechanisms of hepatocellular carcinoma (HCC) are still unclear and new tools for diagnostic and therapeutic purposes are ongoing. We have assessed whether squamous cell carcinoma antigen (SCCA), a serpin overexpressed in neoplastic cells of epithelial origin, is also expressed in liver cancer. Squamous cell carcinoma antigen was evaluated by immunohistochemistry in 65 HCCs of different aetiology and in 20 normal livers. Proliferative activity was assessed using MIB-1 antibody. In 18 surgical samples, tumour and nontumour liver tissue was available for SCCA cDNA amplification and sequencing. Squamous cell carcinoma antigen was detected in 55 out of 65 (85%) tumour specimens, but in none of the 20 controls. In the majority of the cases, the positive signal was found in the cytoplasm of more than 50% of the hepatocytes. Low or undetectable SCCA (score1) was associated to lower MIB-1 labelling index, compared to cases with SCCA score 2 (mean±s.d.: 2%±2.4 vs 7.5%±10.3, P<0.05). Squamous cell carcinoma antigen mRNA could be directly sequenced in 14 out of 18 liver tumours but in none of the corresponding nontumour samples. From sequence alignment, a novel SCCA1 variant (G351 to A) was identified in five cases, while SCCA1 was revealed in six cases and SCCA2 in three cases. In conclusion, SCCA variants are overexpressed in HCC, independently of tumour aetiology. A novel SCCA1 variant has been identified in one third of liver tumours.

2 June 2005 in Cancer
Verified
Journal Article
Open access
PDF file
LBLuca Beneduce
Luca Beneduce
FCFrancesco Castaldi
Francesco Castaldi
MMMaria Marino
Maria Marino
SQSantina Quarta
Santina Quarta
MRMariagrazia Ruvoletto
Mariagrazia Ruvoletto
GFGiorgio Fassina
Giorgio Fassina
BACKGROUND: Early detection of hepatocellular carcinoma (HCC), one of the most common and deadly tumors worldwide, still is difficult due to the lack of adequate biomarkers that show high sensitivity and specificity. The authors recently demonstrated that squamous cell carcinoma antigen (SCCA) variants were overexpressed remarkably in all surgically resected HCCs.METHODS: For the current study, the authors assessed the presence of SCCA, as a free form and complexed with immunoglobulins, in serum from patients with HCC, cirrhosis, and chronic hepatitis and from healthy control participants and compared SCCA measurement with the measurement of α‐fetoprotein (AFP) levels.RESULTS: Circulating immune complexes (ICs) composed by SCCA and immunoglobulin M (IgM) IC (SCCA‐IgM IC) were undetectable (< 120 arbitrary units [AU]/mL) in serum from a healthy control population (0 of 73 controls); however, 35 of 50 patients with HCC (70%) were reactive for SCCA‐IgM IC independent of etiology (mean ± standard deviation [SD], 2568.5 ± 6797.3 AU/mL). No correlation was found with AFP levels, which were elevated significantly in only 21 of 50 patients with HCC (42%). By using an AFP cut‐off value of 20 ng/mL, 96% of patients with HCC were positive for at least 1 marker. Among cirrhotic patients, the presence of circulating SCCA‐IgM IC was displayed in 13 of 50 patients (26%), but at lower levels compared with the patients who had HCC (mean ± SD, 147.5 ± 348.3 AU/mL; P < 0.01; Student t test), whereas 9 of 50 patients with chronic hepatitis (18%) were reactive (mean ± SD, 39.5 ± 89.7 AU/mL). No significant presence of free SCCA, free anti‐SCCA variants IgG or IgM, or SCCA‐IgG IC was found.CONCLUSIONS: The study results indicated that SCCA‐IgM ICs represent novel serologic biomarkers, which, alone or in combination with AFP, can increase the sensitivity for diagnosing HCC significantly. Cancer 2005. © 2005 American Cancer Society.

12 September 1997 in Science
Verified
Journal Article
Closed access
SCStephana Carelli
Stephana Carelli
Aldo CeriottiAldo Ceriotti
Aldo Ceriotti
ACAndrea Cabibbo
Andrea Cabibbo
GFGiorgio Fassina
Giorgio Fassina
MRMenotti Ruvo
Menotti Ruvo
RSRoberto Sitia
Roberto Sitia
Protein folding in the endoplasmic reticulum (ER) often involves the formation of disulfide bonds. The oxidizing conditions required within this organelle were shown to be maintained through the release of small thiols, mainly cysteine and glutathione. Thiol secretion was stimulated when proteins rich in disulfide bonds were translocated into the ER, and secretion was prevented by the inhibition of protein synthesis. Endogenously generated cysteine and glutathione counteracted thiol-mediated retention in the ER and altered the extracellular redox. The secretion of thiols might link disulfide bond formation in the ER to intra- and intercellular redox signaling.